New inhibitors may offer novel approach to treating deadly tuberculosis
Zhong-Yin Zhang, head of Purdue’s Department of Medicinal Chemistry and Molecular Pharmacology, developed highly potent and selective compounds for use in the treatment of tuberculosis. (Image provided)
WEST LAFAYETTE, Ind. – Purdue University innovators have developed highly potent and selective compounds for use in the treatment of tuberculosis, which is one of the top 10 causes of death worldwide.
The Purdue researchers developed a series of small molecule inhibitors to target one of the proteins critical for the survival of TB in infected macrophages. Protein tyrosine phosphates B (mPTPB) is a virulence factor of TB to subvert the host immune responses.
Listen to this article
WEST LAFAYETTE, Ind. â Purdue University innovators have developed highly potent and selective compounds for use in the treatment of tuberculosis, which is one of the top 10 causes of death worldwide.
The Purdue researchers developed a series of small molecule inhibitors to target one of the proteins critical for the survival of TB in infected macrophages. Protein tyrosine phosphates B (mPTPB) is a virulence factor of TB to subvert the host immune responses.
The Purdue research is published in the Journal of Medicinal Chemistry.
âThe death toll from TB is particularly high because of drug-resistant strains,â said Zhong-Yin Zhang, distinguished professor and head of Purdueâs Department of Medicinal Chemistry and Molecular Pharmacology and director of Purdue Institute for Drug Discovery. âThese inhibitors are part of a promising new approach to developing TB therapeutic agents with novel targets and mechanisms of action to help save